SSRI antidepressants observed to protect COVID-19 patients from death

ssri antidepressants observed to protect covid 19 patients from death

Sumary of SSRI antidepressants observed to protect COVID-19 patients from death:

  • Novel research from the US has identified that SSRI antidepressants may possess qualities that help to reduce deaths in COVID-19 patients.
  • The findings of the study supplement previous evidence that SSRI antidepressants can implement beneficial effects against the most severe symptoms of COVID-19. However, a more extensive, randomised clinical trial will be required to prove this.
  • Marina Sirota, PhD, an associate professor of paediatrics and a member of the Bakar Computational Health Sciences Institute (BCHSI) at UC San Francisco, said: “We can’t tell if the drugs are causing these effects, but the statistical analysis is showing significant association.
  • ” COVID-19 protection The Researchers employed electronic health records from the Cerner Real World COVID-19 de-identified database to perform their investigation.
  • This enabled the researchers to understand the effects of age, race, sex, ethnicity, and comorbidities associated with COVID-19, such as heart disease and diabetes, in addition to other medications the patients were taking.
  • Impacts of SSRI antidepressants The results of the study illuminated that individuals taking fluoxetine were 28% less likely to die from COVID-19, and those taking either fluoxetine or another type of SSRI called fluvoxamine were 26% less likely to die.

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close